Ultragenyx agrees to sell FDA priority review voucher for $210 million
Ultragenyx Pharmaceutical agreed to sell a Rare Pediatric Disease Priority Review Voucher to receive $210 million, providing non-dilutive capital for its pipeline.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
6 results loaded, newest first. End of these results.
Ultragenyx to sell priority review voucher for $210 million
Ultragenyx agreed to sell its Rare Pediatric Disease Priority Review Voucher for $210 million in cash. After closing, 20% of gross proceeds will be paid to NIH under a separate license; the transaction is subject to customary closing conditions.
Ultragenyx sells Rare PRV for $210 million
Ultragenyx Pharmaceutical entered a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher for $210 million, subject to customary closing conditions including expiration of the HSR waiting period.
Ultragenyx agrees to sell priority review voucher for $210 million
Ultragenyx said it has entered a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher for $210 million. Closing is subject to customary conditions, including the Hart-Scott-Rodino waiting period.
Ultragenyx agrees to sell PRV for $210 million
Ultragenyx Pharmaceutical entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher for $210 million.
Ultragenyx to sell rare pediatric disease PRV for $210 million
Ultragenyx entered into an agreement to sell a Rare Pediatric Disease Priority Review Voucher for $210 million.